According to Future Market Insights, the Adrenal Crisis Management Market is anticipated to expand at a CAGR of 6.7% between 2023 and 2033. By 2033, it is anticipated that the global market for Adrenal crisis management would reach a value of $6.31 million.
The expansion of the market may be attributable to factors such as the rising incidence of adrenal insufficiency, technological improvements, and increased awareness of the ailment.
The growing prevalence of adrenal insufficiency is one of the primary factors driving the adrenal crisis management industry. A multitude of reasons, including autoimmune illnesses, infections, and the use of certain drugs, contribute to the increasing frequency of adrenal insufficiency.
As the population ages, the incidence of adrenal insufficiency is projected to rise, generating demand for goods and services related to adrenal crisis care.
Innovations in technology have also played a significant influence in the expansion of the adrenal crisis management business. Modern and new diagnostic techniques, such as the ACTH stimulation test and the insulin tolerance test, can reliably detect adrenal insufficiency.
Treatment advancements have also led to market expansion. For instance, novel corticosteroid formulations that are more focused and successful in treating adrenal insufficiency have been created.
Important Findings from the Market Research
The global market for adrenal crisis management is anticipated to expand at a 6.7% CAGR between 2023 and 2033.
In terms of therapy, intravenous injections are anticipated to account for 53% of the market share for adrenal crisis management in 2023.
North America is anticipated to account for 43% of the market for adrenal crisis management in 2023.
Europe’s market share for adrenal crisis treatment is anticipated to reach 41% by 2023.
Increasing awareness of the disease and the need of early diagnosis and appropriate treatment have also contributed significantly to market development, according to an FMI analyst.
Competitive Environment
Bristol-Myers Squibb does research and development on endocrine illnesses, including adrenal insufficiency. The creation of a novel oral drug for the treatment of adrenal insufficiency, which is now undergoing clinical trials, is an example of their research in this field.
Merck KGaA conducts research and development on endocrine illnesses, particularly adrenal insufficiency. Now undergoing clinical trials is the creation of a novel steroid replacement medication for the treatment of adrenal insufficiency, which is an example of their research in this field.
Key participants in adrenal crisis management are:
- Pharmaceuticals firm Eton
- Antares Pharmaceuticals
- Limited Takeda Pharmaceutical Company
- Sandoz International Corporation
- Pfizer Inc.
- Company Bristol-Myers Squibb
- Merck KGaA
- Medications by Mallinckrodt
- Mylan Pharmaceutical Corporation
- Medtronic Plc.
Diagnostic Method:
- Blood Test
- Test of ACTH Stimulation
- Test of Insulin-Induced Hypoglycemia
- Imaging Test
- Therapeutic Method:
- Oral Cortisone
- Hydrocortisone
- Fludrocortisone Acetate
- Intravenous Injections
- Corticosteroids
- Saline Solution
- Sugar (Dextrose) (Dextrose)
- Distribution Method:
- Hospital Drugstore
- Retail Drugstore
- Online Drugstore